The Singapore facility enhances Milliken’s capabilities in Encapsys’ microencapsulation technology, which the company acquired in 2021. Encapsys, a global leader in microencapsulation, brings over 70 years of expertise in developing innovative, patented solutions. The new plant offers improved flexibility and responsiveness to meet customer requirements across Asia.
Ed Zhao, Senior Vice President and Asia Managing Director at Milliken, stated: “This new facility is a testament to our dedication to meet growing demand in this dynamic region.” The investment underscores Milliken’s commitment to strengthening its regional supply chain and supporting industries with specialized material solutions.
Kelly Lai, Vice President of Chemicals and Materials at the EDB, highlighted the significance of the development, saying: “Milliken’s decision to establish its first Asian chemical plant here reflects its confidence in Singapore’s position as a strategic hub for specialty chemicals in the region. The new plant’s advanced manufacturing capabilities will strengthen our chemicals ecosystem and meet growing customer needs in areas such as consumer goods and healthcare.”
The facility is poised to contribute to Singapore’s chemicals sector by delivering cutting-edge solutions for applications in consumer goods, healthcare, and other industries. The EDB emphasized that the plant aligns with Singapore’s role as a key hub for advanced manufacturing, fostering innovation and connectivity for global markets.
Milliken’s expansion in Singapore reflects its strategic focus on meeting the evolving needs of Asian customers while leveraging the city-state’s infrastructure and expertise. The company aims to continue collaborating with regional partners to drive advancements in material technologies, supporting sustainable growth and innovation.
